Keyword: Roivant Sciences
Former Ariad CEO leads Roivant and Arbutus' new RNA JV, Purdue Pharma names new R&D head, Immunomedics poaches AZ I-O exec as R&D chief.
Genevant has RNA technology from Arbutus, $37.5 million in seed funding from Roivant and plans to take 5 to 10 programs into the clinic by 2020.
Celgene COO Scott Smith resigns, ex-Kite leaders Belldegrun and Chang form new CAR-T shop, GSK Dermatology exec jumps to Dermavant.
The Roivant company unveiled the hire alongside other executive appointments and news of the in-licensing of a drug to treat excessive sweating.
A little later than expected, Roivant group company Urovant has started its confirmatory phase 3 program for overactive bladder drug vibegron.
Roivant Sciences is adding a late-phase drug to its pipeline: Nabriva's pneumonia antibiotic lefamulin.
The midphase Type 2 diabetes candidate slots into the pipeline of Roivant’s newly minted cardiometabolic disease startup Metavant.
Roivant and Arbutus have a month to decide if they're going to set up a new company for RNA delivery.
After a very brief and tumultuous tenure at startup Axovant with big hopes and backing, former Medivation chief David Hung, M.D., has resigned as CEO.
The deal ends Poxel’s long wait for a partner capable of running a late-phase diabetes program and starts Roivant’s expansion into metabolic diseases.